<DOC>
	<DOCNO>NCT00215852</DOCNO>
	<brief_summary>To conduct randomize dose-ranging study evaluate safety activity orally administer low dose interferon alfa-n3 immunomodulator subject asymptomatic HIV-1 infection . The primary endpoint study include increase upregulation gene know mediator interferon response . Secondary endpoint include absolute CD4 count plasma HIV RNA level .</brief_summary>
	<brief_title>A Randomized , Dose-ranging Study Alferon LDO Asymptomatic HIV+ Subjects</brief_title>
	<detailed_description>This study open-label , randomize outpatient study HIV infect subject use range dos Alferon LDO . The first nine ( 9 ) patient enrol randomize . Instead , first three ( 3 ) patient receive 500 IU , second three ( 3 ) patient receive 1000 IU , final three ( 3 ) patient receive 2000 IU . Once three ( 3 ) patient give dose level receive least 8 dos without grade 3 toxicity , patient may enrol next high dose level . Following enrollment first nine ( 9 ) patient , additional patient randomize receive one three ( 3 ) dose level Alferon® LDO . The Alferon LDO ( natural interferon alfa-n3 ) buffer solution take orally day 10 consecutive day dose equal 500 IU , 1000 IU , 2000 IU . Pretherapy baseline evaluation perform within three ( 3 ) week period prior randomization . Drug dispense ten day treatment period , time clinical symptom adverse event evaluate . Laboratory sample ( 2.5 ml blood ) microarray analysis evaluation make twice baseline 12-14 hour follow dos 1 , 4 , 10 study day 2 , 5 , 11 , respectively .</detailed_description>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Interferons</mesh_term>
	<mesh_term>Interferon-alpha</mesh_term>
	<criteria>1 . 18 year age old . 2 . HIV1 plasma RNA &gt; 500 copies/ml ( Roche Amplicor assay ) similar assay within 45 day start oral dosing . 3 . Karnofsky performance status 100 4 . Subjects must asymptomatic regard HIV relate clinical symptom include follow opportunistic infection : Oral candidiasis ( thrush ) , cutaneous herpes simplex , fever , diarrhea , weight loss ≥ 10 % body weight , seborrheic dermatitis , chronic mucocutaneous fungal infection Kaposi 's sarcoma . Subjects history AIDS eligible . 5 . Serum creatinine ≤ 1.5 ULN ; serum bilirubin ≤ 2.0 ULN . 6 . Total WBC ≥ 3000/mm3 , platelet count ≥ 100,000/mm3 granulocyte ≥ 1500 mm3 . 7 . Absolute CD4 cell count great 400 ( base average CD4 count two pretherapy test ) . 8 . Hemoglobin &gt; 10.0 g/dl . 9 . AST &lt; 4 time upper normal limit . 10 . ALT &lt; 4 time upper normal limit . 11 . Serum Albumin &gt; 2.0 g/dl . 12 . Written informed consent . 13 . Females must either nonchild bear potential , utilize effective form contraception negative pregnancy test within 14 day entry . 14 . For subject antiretroviral therapy , must stable dose schedule least 90 day prior study entry must continue schedule treatment phase study . 1 . Pregnant nursing woman , woman use effective form contraception . 2 . Less 18 year age . 3 . Active IV drug user . 4 . Absolute CD4 ≤ 400 mm3 ( base average CD4 count two pretherapy test ) . 5 . Receipt immunosuppressive agent , chemotherapy , systemic steroid within 45 day study entry . 6 . Receipt immunomodulator BCG vaccine , isoprinosine , similar experimental agent within 45 day study entry . 7 . Evidence chronic hepatitis , active gastrointestinal , renal , respiratory , endocrine , hematologic , cardiovascular , neurological , psychiatric disorder would limit subject 's ability complete study period . 8 . Unlikely unable comply requirement protocol . 9 . Patients unwilling unable give inform consent . 10 . Patients concurrent experimental medication . 11 . Concurrent , chronic prophylactic use systemic antifungal medication ( e.g . ketoconazole , fluconazole , clotrimazole ) systemic antiviral ( e.g . acyclovir ganciclovir ) except antiretroviral therapy . 12 . Patients use form interferon therapy 6 week prior study entry . If prior interferon therapy receive , subject must know development antibody interferon . 13 . Hospitalized subject , active viral infection HIV , within 2 week study entry . 14 . Transfusion dependent subject ( subject require &gt; 1 unit pack RBC per month within 3 month prior study entry ) . 15 . Subjects symptomatic HIV infection study entry .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2013</verification_date>
	<keyword>Alferon LDO</keyword>
	<keyword>Low Dose Oral Interferon</keyword>
	<keyword>Alfa-n3</keyword>
	<keyword>Human Leukocyte Derived</keyword>
	<keyword>HIV</keyword>
	<keyword>Asymptomatic HIV</keyword>
	<keyword>Treatment Experienced</keyword>
</DOC>